

Limited Submission Funding Opportunities – updated 11/19/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. National Hemophilia Program Coordinating Center (HRSA)

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334384>

MGH LOI Deadline: 11/22/21

Sponsor Application Deadline: 1/24/22

The Health Resources and Services Administration (HRSA) is accepting applications for two separate projects to be awarded in fiscal year (FY) 2022 - HRSA-22-068, the Regional Hemophilia Network (RHN) (Project 1) and HRSA-22-079, the National Hemophilia Program Coordinating Center (NHPCC) (Project 2). The purpose of these programs is to improve access to coordinated, evidence-based care for patients with hemophilia and related bleeding or clotting disorders and their families.

Limited Submission Funding Opportunities – updated 11/19/21

HRSA-22-079: The National Hemophilia Program Coordinating Center (NHPCC) (Project 2): One national coordinating center will strengthen the capacity of the RHN and HTC comprehensive care teams through targeted technical assistance (TA), programmatic support, and data collection to assess patient outcomes.

2. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration Sites

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334407>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

This NOFO, HRSA-22-028 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration Sites, will fund up to 10 demonstration sites to identify, implement, refine, and evaluate emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV with the existing resources and infrastructure of organizations funded through the RWHAP. This funding opportunity will support organizations that have the capacity and infrastructure to successfully execute the project and that have some experience implementing emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV. Working in partnership with the evaluation provider and capacity-building provider, the demonstration sites will participate in evaluating their strategies and developing replication tools for use by other RWHAP recipients and subrecipients.

The demonstration sites must provide comprehensive screening and management of comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV or have an agreement with an organization that can provide these services (referred to as partner organization in the NOFO).

3. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Capacity-Building Provider

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334406>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

This NOFO, HRSA-22-027 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Capacity-Building Provider, will provide technical assistance and capacity development to up to 10 demonstration sites to identify, implement, refine, and evaluate emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV, within the context of the RWHAP; and communicate and dissemination information regarding the initiative. The capacity- building provider will coordinate and implement all activities and products to align with the HAB implementation science framework.

The technical assistance and capacity development activities will consist of learning collaboratives, one-on-one technical consultation, and peer-to-peer exchanges related to identifying, implementing, and refining emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV. The technical assistance and capacity development activities should facilitate the implementation and refinement of the emerging strategies with the existing resources and infrastructure of organizations funded through

Limited Submission Funding Opportunities – updated 11/19/21

the RWHAP. The capacity-building provider will communicate information about the implementation and progress of the initiative throughout its duration and disseminate the evaluation findings and replication tools.

4. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Evaluation Provider <https://www.grants.gov/web/grants/view-opportunity.html?opId=334408>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2022 Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program initiative, Emerging Strategies to Improve Health Outcomes for People Aging with HIV.

This NOFO, HRSA-22-029 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Evaluation Provider, solicits a recipient who will develop and carry out a multi-site evaluation that includes a customized site-specific evaluation for each of the 10 demonstration sites (HRSA-22-028) that will identify, refine, and implement emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV, within the existing resources and infrastructure of organizations funded through the RWHAP. In addition to the site-specific components, the evaluation will include cross-site components that are consistent across all of the demonstration sites. The evaluation provider's activities and products will align with the HAB implementation science framework. Throughout this initiative, the evaluation provider will work closely with the demonstration sites (HRSA-22-028) and capacity-building provider (HRSA-22-027). The capacity-building provider will lead and implement the dissemination plan, which will include the evaluation findings produced by the evaluation provider.

5. Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-321.html>

MGH LOI Deadline: 12/01/21

NIH Application Deadline: 1/25/22

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community

Limited Submission Funding Opportunities – updated 11/19/21

6. Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PA-21-312.html>

MGH LOI Deadline: 12/06/21

NIH Application Deadline: 1/25/22

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on **Curriculum Development**. This NHGRI R25 program offers to support the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine and/or genomic informatics for medical students. Specifically, this FOA will support the development of curriculum designed to be freely available, at no cost to the broader community to enhance training in genomics for medical students.

7. SUNBEAM – Analysis and Bioinformatics Center (ABC) (UM1 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-060.html>

MGH LOI Deadline: 12/08/21

NIH LOI Deadline: 1/15/22

NIH Application Deadline: 2/15/22

The purpose of the SUNBEAM - Analysis and Bioinformatics Center (SUNBEAM-ABC) is to establish a mechanistic omics center to support the birth cohort study Systems Biology of Early Atopy (SUNBEAM). The center will assay biologic samples collected within the SUNBEAM cohort using omics and systems biology approaches to identify determinants of atopic disease, focusing on food allergy and atopic dermatitis (AD) in newborns, infants, and very young children. SUNBEAM-ABC will support the SUNBEAM birth cohort study by providing analytic infrastructure for a comprehensive understanding of molecular and cellular pathways that contribute to atopic disease development and to identify early predictive biomarkers.

8. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-060.html>

MGH LOI Deadline: 12/15/21

NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

Limited Submission Funding Opportunities – updated 11/19/21

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOAs ([RFA-CA-21-061](#) or [RFA-CA-21-062](#)).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences). In addition, please indicate the RFA that you will submit your application under.

9. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-061.html>

MGH LOI Deadline: 12/15/21

NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ([RFA-CA-21-060](#)).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences). In addition, please indicate the RFA that you will submit your application under.

10. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-062.html>

MGH LOI Deadline: 12/15/21

NIH Application Deadline: 2/28/22

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these

Limited Submission Funding Opportunities – *updated 11/19/21*

fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ([RFA-CA-21-060](#)).

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA ([RFA-CA-21-060](#)).

For your LOI to ECOR, please indicate the scientific area that you will be submitting under (Data Science, Cancer Control Science, or Other Sciences). In addition, please indicate the RFA that you will submit your application under.